Insulet Corporation vs Eli Lilly & Co.
PODD vs LLY — side-by-side comparison from reported financials. PODD leads 3, LLY leads 8 of 11 comparable metrics.
Insulet Corporation
PODD · Healthcare
$135.28+0.60%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | PODD | LLY |
|---|---|---|
| Price | $135.28 | $1 177.20 |
| Market cap | $9.38B | $1.05T |
| Revenue (TTM) | $3.05B | $79.7B |
| Revenue growth | +27.5% | +31.7% |
| Net margin | 12.3% | 33.5% |
| Free cash flow | $294M | $18.2B |
| Net cash (debt) | ($215M) | ($35.2B) |
| 1-year price return | -57.8% | +37.6% |
| P/E | 25.0 | 41.6 |
| P/E vs own history (cheap-side %) | 99% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 17% | 93% |
| Altman Z-score | 4.61 | 7.10 |
| CV checks passed | 10 of 10 | 11 of 10 |
| Employees | 5,400 | 50,000 |
Full résumé-style profiles: PODD CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.